Literature DB >> 15603973

5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

Stephen W Wright1, Virginia L Rath, Paul E Genereux, David L Hageman, Carolyn B Levy, Lester D McClure, Scott C McCoid, R Kirk McPherson, Teresa M Schelhorn, Donald E Wilder, William J Zavadoski, E Michael Gibbs, Judith L Treadway.   

Abstract

The synthesis, in vitro, and in vivo biological characterization of a series of achiral 5-chloroindoloyl glycine amide inhibitors of human liver glycogen phosphorylase A are described. Improved potency over previously reported compounds in cellular and in vivo assays was observed. The allosteric binding site of these compounds was shown by X-ray crystallography to be the same as that reported previously for 5-chloroindoloyl norstatine amides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15603973     DOI: 10.1016/j.bmcl.2004.10.048

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Molecular modeling and QSAR studies of a set of indole and benzimidazole derivatives as H₄ receptor antagonists.

Authors:  João Paulo S Fernandes; Kerly Fernanda M Pasqualoto; Elizabeth I Ferreira; Carlos A Brandt
Journal:  J Mol Model       Date:  2010-07-06       Impact factor: 1.810

2.  Outliers in SAR and QSAR: 4. effects of allosteric protein-ligand interactions on the classical quantitative structure-activity relationships.

Authors:  Ki Hwan Kim
Journal:  Mol Divers       Date:  2022-02-22       Impact factor: 3.364

3.  An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.

Authors:  S M Poucher; S Freeman; S J G Loxham; G Convey; J B Bartlett; J De Schoolmeester; J Teague; M Walker; A V Turnbull; A D Charles; F Carey; S Berg
Journal:  Br J Pharmacol       Date:  2007-10-15       Impact factor: 8.739

4.  Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations.

Authors:  Liying Zhang; Chengjun Song; Guangxin Miao; Lianzhi Zhao; Zhiwei Yan; Jing Li; Youde Wang
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

Review 5.  Discovery and Biotechnological Exploitation of Glycoside-Phosphorylases.

Authors:  Ao Li; Mounir Benkoulouche; Simon Ladeveze; Julien Durand; Gianluca Cioci; Elisabeth Laville; Gabrielle Potocki-Veronese
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.